u/forest_plot_fiona
Confidence intervals are the entire story. The point estimate is the headline.
long-standing contributor · stats · joined 19 Nov 2023
Overview — page 3 of 3
comment on [Discussion] can we stop arguing about lipids until somebody posts a number in c/bloodwork · 164 points · 1 year ago
Brought the whole set to my clinician rather than one flagged value. Completely different conversation.
comment on help me understand SURMOUNT, I have read the wiki twice in c/trialwatch · 126 points · 1 year ago
Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.
comment on how much of what we believe about dual agonist actually comes from GIP threads in c/tirzepatide · 13 points · 1 year ago
hold the dose that works, the ladder is not a leaderboard
comment on help me understand SURMOUNT, I have read the wiki twice in c/trialwatch · 102 points · 1 year ago
Left up and flaired Trial Data. The publication is linked rather than the coverage, which is what we ask for.
comment on CagriSema — my 2-week log, condensed into one table in c/cagrilintide · 247 points · 1 year ago
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
comment on [Question] how do you actually verify cycle in c/glp1women · 35 points · 1 year ago
How many cycles has the pattern held for?
comment on the satiety question that gets asked weekly, answered properly in c/cagrilintide · 16 points · 1 year ago
long-acting amylin is the whole point of the molecule
comment on [Meta] the FLOW rule is doing its job and people should stop complaining in c/trialwatch · 6 points · 1 year ago
Retitled: the original quoted a diabetes endpoint as an obesity result.
comment on hazard ratio is the most under-discussed thing on this board in c/trialwatch · 134 points · 1 year ago
Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.
comment on anyone else notice GIP kicking in around week 81 in c/tirzepatide · 5 points · 1 year ago
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
comment on reading cagrilintide threads from 2024 and half of it aged badly in c/cagrilintide · 9 points · 1 year ago
read the combination arms separately from the monotherapy arms
comment on nobody warned me about reflux and I would have liked the warning in c/bloodwork · 129 points · 2 years ago
ask whether the lab changed its assay between your two draws
comment on am I the only one who found Zepbound harder than the injections in c/tirzepatide · 14 points · 2 years ago
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
comment on [Lab] split one vial across Medutest and Janoshik — 98.3% and 98.7% in c/tirzepatide · 257 points · 2 years ago
The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.
comment on the STEP thing finally clicked for me and I want to write it down in c/trialwatch · 19 points · 2 years ago
The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.
comment on the STEP thing finally clicked for me and I want to write it down in c/trialwatch · 56 points · 2 years ago
The press release said that; the publication says something more hedged. Worth reading both.
comment on how much of what we believe about ApoB actually comes from baseline labs threads in c/bloodwork · 46 points · 2 years ago
Push back: a value just outside a reference interval is a common finding in healthy people. It is a reason to repeat.
comment on [Question] how do you actually verify GIP in c/tirzepatide · 60 points · 2 years ago
Same experience with the appetite effect being flatter across the week rather than front-loaded.
comment on [Meta] the SURMOUNT rule is doing its job and people should stop complaining in c/tirzepatide · 18 points · 2 years ago
Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.